肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

The Oncologist：女性乳腺癌患者伴有无症状和有症状脑转移的治疗模式和预后：单中心回顾性研究

2021-09-24 yd2015 MedSci原创

乳腺癌脑转移
关注

研究发现，尽管SRS的应用，乳腺癌脑转移患者的预后仍然较差。今后仍需更多研究发现早期脑转移的策略和治疗方式。

乳腺癌是全世界女性中最常见的癌症，也是脑转移(BrM)的第二大原因。尽管最近的治疗进展，乳腺癌患者BrM的预后仍然很差，尤其是HER2阴性亚型患者。虽然乳腺癌BrM患者的死亡原因尚不明确，但大约50%的HER2+ BrM患者被认为死于中枢神经系统(CNS)疾病累及。脑转移的治疗包括手术，全脑放疗以及全身系统性治疗。而现代立体定向放射治疗(SRS)高效低毒的优点常被用于临床实践。近期，国外学者开展了单中心回顾性研究，评估女性乳腺癌患者脑转移治疗的模式[手术、全脑放疗（WBRT）以及立体定向放疗（SRS）] 和预后。相关结果发表在The Oncologist杂志上。

研究纳入683例患者，诊断BrM的中位年龄为56岁(范围24-93)，诊断转移性乳腺癌（MBC）到发展为脑转移（BrM）的中位时间为8.1个月( [IQR] 0-24.4)。乳腺癌亚型的分布频率如下:153例(22.4%)TNBC, 188例(27.5%)HER2+， 246例(36.0%)HR+/HER2-， 61例(13.3%)患者亚型不明。

           临床特征

BrM最常见的一线治疗方式是WBRT (n = 459, 67.2%)，其次是SRS (n = 126, 18.4%)和手术切除(n = 69, 10.1%)。相对于无神经症状脑转移患者，诊断BrM时伴有神经系统症状(n = 529, 77.5%)更有可能需要接受手术切除(风险比(RR) = 2.74)和不太可能使用SRS治疗 (19.1% vs 32.7%,RR = 0.53)。在117例无症状患者中，107例(91.4%)接受放射治疗，5例(4.3%)接受手术作为一线局部治疗。

        治疗方式

总体人群中中位颅内特异性无进展生存期（bsPFS）为4.1 个月(IQR 1.0–9.6)。总体人群的中位OS为5.1个月(IQR 2.0-11.7)。相对于一线应用WBRT治疗的患者，使用手术治疗 (HR=0.20; 95% CI, 0.08–0.49) 或SRS (HR=0.37; 95% CI, 0.22–0.63) 治疗的患者预后更好。HER2+ MBC患者比TNBC 和 HR+/HER2-患者的中位OS(12.2 vs. 3.6 vs. 4.4个月)以及bsPFS (7.0 vs. 3.1 vs. 3.8个月)更优。

             OS对比

综上，研究发现，尽管SRS的应用，乳腺癌脑转移患者的预后仍然较差。今后仍需更多研究发现早期脑转移的策略和治疗方式。

原始出处：

Y IZHUO K ELLY G AO , M ARKUS K UKSIS , B ADR I D S AID , et al. Treatment Patterns and Outcomes of Women with Symptomatic and Asymptomatic Breast Cancer Brain Metastases: A Single-Center Retrospective Study. The Oncologist 2021;9999:1–11 www.TheOncologist.com

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1866249, encodeId=8d5e186624958, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 18 02:19:56 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455181, encodeId=52e51455181a0, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485215, encodeId=4f361485215b0, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555161, encodeId=cbaa155516120, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571286, encodeId=215015e1286cf, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585718, encodeId=a4061585e1856, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054624, encodeId=a52a10546242c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210925/2c1679ed9157495fae06921b994dee45/2fc311623d30433e92297831c3dd3394.jpg, createdBy=bf2b2589287, createdName=39294663, createdTime=Sat Sep 25 07:38:47 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054614, encodeId=6011105461422, content=学习了◉‿◉, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210627/0e8142bbb4a04eb78e71a2d739e0aac0/4a0cee7114594824a0a9903ac1495565.jpg, createdBy=c9e91732173, createdName=Angela Yu, createdTime=Sat Sep 25 06:53:44 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
    2022-04-18 minlingfeng

    #Oncol#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1866249, encodeId=8d5e186624958, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 18 02:19:56 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455181, encodeId=52e51455181a0, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485215, encodeId=4f361485215b0, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555161, encodeId=cbaa155516120, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571286, encodeId=215015e1286cf, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585718, encodeId=a4061585e1856, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054624, encodeId=a52a10546242c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210925/2c1679ed9157495fae06921b994dee45/2fc311623d30433e92297831c3dd3394.jpg, createdBy=bf2b2589287, createdName=39294663, createdTime=Sat Sep 25 07:38:47 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054614, encodeId=6011105461422, content=学习了◉‿◉, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210627/0e8142bbb4a04eb78e71a2d739e0aac0/4a0cee7114594824a0a9903ac1495565.jpg, createdBy=c9e91732173, createdName=Angela Yu, createdTime=Sat Sep 25 06:53:44 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
    2021-09-26 july_977

    #GIST#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1866249, encodeId=8d5e186624958, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 18 02:19:56 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455181, encodeId=52e51455181a0, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485215, encodeId=4f361485215b0, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555161, encodeId=cbaa155516120, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571286, encodeId=215015e1286cf, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585718, encodeId=a4061585e1856, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054624, encodeId=a52a10546242c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210925/2c1679ed9157495fae06921b994dee45/2fc311623d30433e92297831c3dd3394.jpg, createdBy=bf2b2589287, createdName=39294663, createdTime=Sat Sep 25 07:38:47 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054614, encodeId=6011105461422, content=学习了◉‿◉, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210627/0e8142bbb4a04eb78e71a2d739e0aac0/4a0cee7114594824a0a9903ac1495565.jpg, createdBy=c9e91732173, createdName=Angela Yu, createdTime=Sat Sep 25 06:53:44 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
    2021-09-26 12498da4m34(暂无昵称)

    #无症状#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1866249, encodeId=8d5e186624958, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 18 02:19:56 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455181, encodeId=52e51455181a0, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485215, encodeId=4f361485215b0, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555161, encodeId=cbaa155516120, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571286, encodeId=215015e1286cf, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585718, encodeId=a4061585e1856, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054624, encodeId=a52a10546242c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210925/2c1679ed9157495fae06921b994dee45/2fc311623d30433e92297831c3dd3394.jpg, createdBy=bf2b2589287, createdName=39294663, createdTime=Sat Sep 25 07:38:47 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054614, encodeId=6011105461422, content=学习了◉‿◉, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210627/0e8142bbb4a04eb78e71a2d739e0aac0/4a0cee7114594824a0a9903ac1495565.jpg, createdBy=c9e91732173, createdName=Angela Yu, createdTime=Sat Sep 25 06:53:44 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
    2021-09-26 yankaienglish

    #治疗模式#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1866249, encodeId=8d5e186624958, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 18 02:19:56 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455181, encodeId=52e51455181a0, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485215, encodeId=4f361485215b0, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555161, encodeId=cbaa155516120, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571286, encodeId=215015e1286cf, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585718, encodeId=a4061585e1856, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054624, encodeId=a52a10546242c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210925/2c1679ed9157495fae06921b994dee45/2fc311623d30433e92297831c3dd3394.jpg, createdBy=bf2b2589287, createdName=39294663, createdTime=Sat Sep 25 07:38:47 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054614, encodeId=6011105461422, content=学习了◉‿◉, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210627/0e8142bbb4a04eb78e71a2d739e0aac0/4a0cee7114594824a0a9903ac1495565.jpg, createdBy=c9e91732173, createdName=Angela Yu, createdTime=Sat Sep 25 06:53:44 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
    2021-09-26 hanhaisha2013

    #乳腺癌患者#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1866249, encodeId=8d5e186624958, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 18 02:19:56 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455181, encodeId=52e51455181a0, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485215, encodeId=4f361485215b0, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555161, encodeId=cbaa155516120, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571286, encodeId=215015e1286cf, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585718, encodeId=a4061585e1856, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054624, encodeId=a52a10546242c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210925/2c1679ed9157495fae06921b994dee45/2fc311623d30433e92297831c3dd3394.jpg, createdBy=bf2b2589287, createdName=39294663, createdTime=Sat Sep 25 07:38:47 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054614, encodeId=6011105461422, content=学习了◉‿◉, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210627/0e8142bbb4a04eb78e71a2d739e0aac0/4a0cee7114594824a0a9903ac1495565.jpg, createdBy=c9e91732173, createdName=Angela Yu, createdTime=Sat Sep 25 06:53:44 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
    2021-09-26 jiyangfei

    #回顾性研究#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1866249, encodeId=8d5e186624958, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 18 02:19:56 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455181, encodeId=52e51455181a0, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485215, encodeId=4f361485215b0, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555161, encodeId=cbaa155516120, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571286, encodeId=215015e1286cf, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585718, encodeId=a4061585e1856, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054624, encodeId=a52a10546242c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210925/2c1679ed9157495fae06921b994dee45/2fc311623d30433e92297831c3dd3394.jpg, createdBy=bf2b2589287, createdName=39294663, createdTime=Sat Sep 25 07:38:47 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054614, encodeId=6011105461422, content=学习了◉‿◉, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210627/0e8142bbb4a04eb78e71a2d739e0aac0/4a0cee7114594824a0a9903ac1495565.jpg, createdBy=c9e91732173, createdName=Angela Yu, createdTime=Sat Sep 25 06:53:44 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
    2021-09-25 39294663

    学习了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1866249, encodeId=8d5e186624958, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Apr 18 02:19:56 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455181, encodeId=52e51455181a0, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485215, encodeId=4f361485215b0, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555161, encodeId=cbaa155516120, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571286, encodeId=215015e1286cf, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585718, encodeId=a4061585e1856, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Sun Sep 26 11:19:56 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054624, encodeId=a52a10546242c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210925/2c1679ed9157495fae06921b994dee45/2fc311623d30433e92297831c3dd3394.jpg, createdBy=bf2b2589287, createdName=39294663, createdTime=Sat Sep 25 07:38:47 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054614, encodeId=6011105461422, content=学习了◉‿◉, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210627/0e8142bbb4a04eb78e71a2d739e0aac0/4a0cee7114594824a0a9903ac1495565.jpg, createdBy=c9e91732173, createdName=Angela Yu, createdTime=Sat Sep 25 06:53:44 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
    2021-09-25 Angela Yu

    学习了◉‿◉

    0